Cipla Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla reported consolidated revenue from operations of ₹6,957.47 crores in Q1FY26, up about 3.9% from ₹6,693.94 crores in Q1FY25. Consolidated net profit rose roughly 9.9% to ₹1,291.61 crores from ₹1,175.46 crores, with EPS at ₹15.13 versus ₹14.58. On a standalone basis, revenue grew about 12.1% to ₹5,046.17 crores and net profit jumped roughly 23.4% to ₹1,303.13 crores, with standalone EPS of ₹16.13. The Pharmaceuticals segment contributed ₹6,579.42 crores in revenue, while the New Ventures segment turned profitable at ₹56.76 crores compared with a small loss a year ago. The auditor (Walker Chandiok & Co LLP) issued an unmodified limited review conclusion on both sets of results.
Steady, broad-based growth with margin expansion at the standalone level, driven by both the core Pharma and improving New Ventures businesses — likely to be viewed positively by investors. No new exceptional items in the quarter and a clean auditor opinion remove near-term concerns, though the long-standing NPPA overcharge matter (aggregate exposure of around ₹2,011 crores) remains an overhang worth watching.